Sectors
Quentis, an immuno-oncology therapy developer based on research at Weill Cornell Medicine, has closed a round that included Taiho Pharmaceuticals and AbbVie Ventures.
Partly based on Keio University research, CureApp has developed mobile apps to help treat nicotine addiction and fatty liver inflammation.
The Global University Venturing deal net rounds up all the latest smaller deals and tracks emerging companies accessing university funds.
The business school hopes the partnership will strengthen the ecosystem, leveraging its faculty, program participants and alumni network for the initiative.
Based on research conducted at Caltech and Nasa, Virtualitics has now raised more than $11m in funding for its VR data visualisation and analytics platform.
The Medical Research Commercialisation Fund has supplied series A capital to Okogen as the company partners University of Sydney to develop a treatment for viral conjunctivitis.
The UC Berkeley-affiliated House Fund is seeking up to $50m for its second vehicle, after closing a $6m fund in 2016.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
